(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 September 2023 (28.09.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/183428 A8

(51) International Patent Classification:
A61K 31/44 (2006.01) *A61K 31/395* (2006.01)
A61K 31/42 (2006.01) *A61K 31/33* (2006.01)

(21) International Application Number:
PCT/US2023/015966

(22) International Filing Date:
22 March 2023 (22.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/322,446 22 March 2022 (22.03.2022) US

(71) Applicants: **ALLYX THERAPEUTICS, INC.** [US/US]; 470 James Street, Suite 007, New Haven, CT 06513 (US). **YALE UNIVERSITY** [US/US]; Two Whitney Avenue, New Haven, CT 06510 (US).

(72) Inventors: **SIEGERT, Timothy, Ryan**; 470 James Street, Suite 007, New Haven, CT 06513 (US). **STRITTMATTER, Stephen**; Two Whitney Avenue, New Haven, CT 06510 (US). **SCARAVELLI, Federico**; Campus Levi-Montalcini, Via Alessandro Fleming, 4, 37135 Verona (IT). **CORÁ, Camilla**; Campus Levi-Montalcini, Via Alessandro Fleming, 4, 37135 Verona (IT).

(74) Agent: **MCDONALD, Cooper J.** et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
14 December 2023 (14.12.2023)

(15) Information about Correction:
see Notice of 14 December 2023 (14.12.2023)

WO 2023/183428 A8

(54) Title: MGLUR5 MODULATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

(57) Abstract: The present disclosure provides compositions of (4R,5R)-5-(2-chlorophenyl)-4-(5- (phenylethynyl)pyridin-3-yl)oxazolidin-2-one (Compound 1). Crystalline and solvate forms of the compound and formulations comprising the compound are also provided. Methods of using the compound and methods of administering the formulations to a subject in need thereof are provided to treat or prevent CNS disorders such as Alzheimer's disease.